https://www.selleckchem.com/pr....oducts/n-acetyl-dl-m
In a pooled population analysis, we investigated the pharmacokinetics of intravenous (IV) anidulafungin in four studies across a full range of adult and pediatric ages in patients with confirmed, suspected, or at high risk of invasive candidiasis (IC). Relationships between anidulafungin exposure and key efficacy endpoints (global response of success and all-cause mortality) and safety endpoints (all-cause hepatic or gastrointestinal adverse events) in all patients and separately in pediatric patients and the appropriate
Like
Comment
Share
